Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

480
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
480
Cancer Vaccines01:30

Cancer Vaccines

340
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
340
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Real-World Outcomes with BCMA- and GPRC5D-Targeting Bispecific Antibodies in Plasma Cell Leukemia.

Blood advances·2026
Same author

Arlocabtagene autoleucel-a GPRC5D-targeted CAR T-cell therapy in heavily pretreated relapsed/refractory multiple myeloma.

Blood·2026
Same author

Targeting BCMA in Patients with Relapsed/Refractory Multiple Myeloma in 1-3 Prior Lines of Therapy.

Blood advances·2026
Same author

Early mortality with bispecific antibody therapy in RRMM: an IMWG immunotherapy database real-world analysis.

Blood advances·2026
Same author

Distinct trajectory of measurable residual disease in t(11;14) myeloma treated with quadruplet therapy.

Blood·2026
Same author

Alnuctamab, a bivalent B-cell maturation antigen-targeting T cell engager for patients with relapsed or refractory multiple myeloma: results from a phase 1, first-in-human study.

Leukemia·2026
Same journal

BTK Degraders in Lymphoid Malignancies: New Modality, New Resistance Rules?

Blood cancer discovery·2026
Same journal

Tumor-infiltrating clonal hematopoiesis is associated with adverse clinical outcomes in diffuse large B-cell lymphoma.

Blood cancer discovery·2026
Same journal

Beyond Static Subtypes in Large B-cell Lymphoma: Context, Plasticity, and Therapeutic Logic.

Blood cancer discovery·2026
Same journal

A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma.

Blood cancer discovery·2026
Same journal

Genomic features do not account for differences in multiple myeloma risk by ancestry.

Blood cancer discovery·2026
Same journal

Outcomes of CAR-T Cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma.

Blood cancer discovery·2026
查看所有相关文章

相关实验视频

Updated: Jun 6, 2025

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells
12:08

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

9.2K

总体 (免疫) 疗法:版本2.0

Susan Bal1,2, Luciano J Costa1,2

  • 1Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, Alabama.

Blood cancer discovery
|November 26, 2024
PubMed
概括
此摘要是机器生成的。

自生化学抗原受体T细胞疗法对患有多抗性髓瘤的患者显示出很大的前景. 将这种疗法与双特异性抗体相结合,提供了一种全新的免疫治疗策略.

更多相关视频

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.3K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

461

相关实验视频

Last Updated: Jun 6, 2025

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells
12:08

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

9.2K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.3K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

461

科学领域:

  • 免疫治疗是一种免疫疗法.
  • 在瘤学瘤学.
  • 血液学 血液学 血液学

背景情况:

  • 多发性骨髓瘤是一种血液性恶性瘤,对于患有多重耐药性疾病的患者来说,治疗选择有限.
  • 自体仿真抗原受体T细胞疗法已成为耐火性癌症的有前途的治疗方式.

研究的目的:

  • 探索自化基因抗原受体T细胞疗法在多抗性髓瘤中的潜力.
  • 讨论将仿真抗原受体T细胞疗法与双特异抗体相结合的可行性,以进行综合性免疫治疗方法.

主要方法:

  • 对多发性骨髓瘤中仿真抗原受体T细胞治疗的当前文献和临床数据的综述.
  • 分析双特异抗体在免疫治疗策略中的作用和整合.

主要成果:

  • 自生化学抗原受体T细胞疗法在患有多抗性髓瘤的患者中显示出显著的潜力.
  • 双特异性抗体的出现使得一种结合免疫治疗策略与仿制抗原受体T细胞疗法在临床上是可行的.

结论:

  • 化学抗原受体T细胞疗法对那些在多抗性髓瘤中治疗选择有限的患者来说是一个重要的进步.
  • 一种结合免疫疗法方法,利用化学抗原受体T细胞疗法和双特异性抗体,为管理耐火性多发性髓瘤提供了一个有希望的未来方向.